Complement C4 genes are linked to paediatric inflammatory bowel disease (PIBD), but the mechanisms have remained unclear. We examined the influence of C4B gene number on intestinal microbiota and in-vitro serum complement activation by intestinal microbes in PIBD patients. Complement C4A and C4B gene numbers were determined by genomic reverse transcription-polymerase chain reaction (RT-PCR) from 64 patients with PIBD (Crohn's disease or ulcerative colitis). The severity of the disease course was determined from faecal calprotectin levels. Intestinal microbiota was assessed using the HITChip microarray. Complement reactivity in patients was analysed by incubating their sera with Yersinia pseudotuberculosis and Akkermansia muciniphila and determining the levels of C3a and soluble terminal complement complex (SC5b-9) using enzyme immunoassays. The microbiota diversity was wider in patients with no C4B genes than in those with one or two C4B genes, irrespective of intestinal inflammation. C4B and total C4 gene numbers correlated positively with soluble terminal complement complex (TCC, SC5b-9) levels when patient serum samples were stimulated with bacteria. Our results suggest that the C4B gene number associates positively with inflammation in patients with PIBD. Multiple copies of the C4B gene may thus aggravate the IBDassociated dysbiosis through escalated complement reactivity towards the microbiota.
Introduction
Ulcerative colitis, Crohn's disease and unclassified colitis constitute the major forms of chronic inflammatory bowel disease (IBD). The symptoms of these chronic inflammatory diseases of the gastrointestinal tract include severe abdominal pain, diarrhoea and weight loss. The diseases are multi-factorial and are associated with genetic predisposition, environmental factors, changes in the intestinal microbiota and their interactions with the surroundings [1] . Genomewide association studies have identified common variants in more than 160 genes that contribute to the genetic susceptibility to IBD [2] . Many of the contributing genes code for proteins involved in innate immune responses, which are initiated by the complement system [3, 4] . Disease aetiology is therefore thought to involve perturbed host-microbiota interactions, due either to abnormal reactions to the normal microbiota or aberrant microbiota development eliciting inflammatory host responses [5] .
The complement system has a critical role in maintaining the tissue homeostasis by eliminating excess bacteria and cellular debris. Complement C4 is an important component of the classical and lectin pathways, which are involved in tissue clearance and microbial elimination. C4 genes locate in the centre of the major histocompatibility complex (MHC) class III region (6p 21.3). There are two different C4 genes (C4A and C4B) that vary in number between individuals. In most cases an individual has two C4A and two C4B genes, four in total [6] . C4B participates in the host defence against intestinal microbes, and C4B deficiencies have been associated with susceptibility to infections caused by, e.g. encapsulated bacteria [7] [8] [9] [10] [11] .
C4A deficiencies have been associated mainly with susceptibility to inflammatory [12] and autoimmune diseases [13, 14] . We recently discovered a novel association between the MHC-haplotype (HLA-A*03; HLA-B*07; 1 C4A gene; 1 C4B gene; HLA-DRB1*15) and paediatric IBD (PIBD). We also found that PIBD patients deficient in C4B (fewer than two C4B genes) recovered poorly after surgery [15] .
Studies of intestinal microbiota with IBD patients have shown a decreased bacterial diversity and changes in microbiota composition in the faecal samples and colonic biopsies compared to healthy controls [16] [17] [18] . Reduced levels of butyrate producers and Akkermansia muciniphila have been detected in patients with IBD (mainly ulcerative colitis) [19, 20] . A. muciniphila is a bacterium specialized to mucin degradation and a key organism at the mucosal interface between the lumen and host cells [21] . Both butyrate producers and A. muciniphila are considered important for healthy gut barrier function and have antiinflammatory effects. An altered balance of beneficial and aggressive bacteria within gut microbiota is often connected to damage of the intestinal barrier ('leaky gut') [22] . Increased amounts of aerobic Gram-negative bacteria, which produce highly inflammatory lipopolysaccharide (LPS), have often been found in IBD patients. One of these is Yersinia pseudotuberculosis (Y. pseudotuberculosis), a food-borne Gram-negative pathogen related to gut commensals, but can be aggressive and cause intestinal gastroenteritis in humans [23] . In the present study we used these two bacteria, A. muciniphila and Y. pseudotuberculosis, as examples to stimulate complement activation in patient sera and studied the influence of C4 gene number (indicating the number of C4A or/and C4B genes) and protein amount on the complement activation capacity. In addition, the influence of C4 gene numbers on intestinal microbiota and inflammation was assessed in PIBD patients. Addressing the gene copy number variation, and particularly that occurring in the MHC region, is important and needs to be performed separately, because it is not usually analysed in genome-wide association studies.
Materials and methods

Study populations
The PIBD patients were part of a larger study population that has been described previously [15, 18] . For the present study we included patients (n 5 47) who had data on their C4 genotype and who participated in our previous microbiota study [18] (the Microbiota Study) and the patients (n 5 26), who donated blood samples for bacterial stimulation for the complement activation study (the Complement Study) in 2013 [15] . A total of 64 patients was included, as nine provided samples for both studies. Patients were invited to the Complement Study based on their C4B genotype gene number (to obtain enough patients in each genotype group).
The severity of the PIBD disease course was evaluated from the patient charts and classified by physicians' global assessment into three categories: class 1 as mild (no regular medication needed), class 2 (regular medication with good disease control, need of immune suppressants and/or biological medications) as moderate or class 3 (poor disease control) as severe. The physicians' global assessment was assessed at the same time that faecal and serum samples were collected, as described previously [24] . At this point the patients were all in good disease control (classes 1 and 2). Levels of inflammation at the time of faecal sample collection were assessed by measuring faecal calprotectin levels using a quantitative enzyme immunoassay (PhiCal Test; Calpro AS, Oslo, Norway). A calprotectin result of < 100 lg/g in stools was considered normal, whereas results of > 1000 lg/g were considered to be exceedingly high [25] [26] [27] [28] [29] .
Ethics statement
The study on inflammatory markers in paediatric-onset IBD was approved by the Ethics Committee of the Helsinki University Central Hospital (371/E7/2004, 25th amendment, January 2012). The patients or their guardians signed an informed consent form to participate in this study at the diagnosis or at the start of therapy with glucocorticoids or infliximab.
Microbiota analysis (the Microbiota Study)
The patients' microbiota has been described previously [18] . Briefly, patients (n 5 47) were requested to provide two stool samples for the measurement of faecal calprotectin and for microarray analysis. The faecal samples were frozen at 2208C within 4 h of defecation and stored at 2708C until analysis. DNA was extracted from the stool samples using the repeated bead beating method [30] . We have previously calculated the similarity to the control microbiota index for these patients, which characterizes how similar the microbiota composition is to the composition in non-PIBD individuals [18] . Briefly, the index was an average of the correlations between the microbiota of a patient and with subjects (n 5 26) with healthy intestine, determined by low calprotectin levels [18] . Composition of the intestinal microbiota was analysed with a phylogenetic microarray, the HITChip [31] , consisting of oligonucleotide probes, the intensities of which were summarized using the Robust Probabilistic Averaging (RPA) for probelevel analysis method [32] as 1038 species-level bacterial phylotypes. These phylotypes were categorized further into 130 genus-level groups as described previously [31] . All microarray experiments were repeated at least twice and only replicate hybridizations with high reproducibility (> 98% Pearson similarity) were used for further analysis. 
Genetic analyses
Genomic DNA was extracted from 64 patients and C4 gene numbers were assessed from the previously analysed genomic data, as detailed previously [15, 33] . The patients were divided into groups based on the C4B gene numbers, the C4A gene numbers and the total number of C4 genes. In the Complement Study, the patients were also divided into groups for C4 deficiency (patients with fewer than four genes of C4A and C4B) and no C4 deficiency (patients with four or more genes of C4A and C4B). Analysis of C4A included the detection of the common CT-insertion (CTins MIM 1 120810) that leads to silencing of C4A gene [6] . Thus, our analysis included the total number of functional C4A genes. Two patients had the insertion.
Bacterial stimulation of complement in patient sera (the Complement Study)
The Y. pseudotuberculosis serotype O:3 (YIII/PIB1) strain and sera from Y. pseudotuberculosis-infected patients were provided by Professor Mikael Skurnik at the University of Helsinki [34] . For the complement activity assays, Y. pseudotuberculosis was grown in Luria-Bertani broth at 1 378C for 17 h. The bacteria were suspended into fresh Luria-Bertani medium and cultured for 7 h to reach optical density (OD) 600 0Á2-0Á6. After washing the Y. pseudotuberculosis bacteria with phosphate-buffered saline (PBS), they were mixed with PBS containing 3% formalin and incubated for 30 min at 378C with intensive shaking to kill the bacteria. Bacterial cells were frozen in PBS with 1% bovine serum albumin and 0Á1% sodium azide at 2708C. A. muciniphila was grown as described previously [35] .
For serum complement activation, Y. pseudotuberculosis and A. muciniphila bacterial cells were washed three times with PBS and adjusted to obtain 10 9 cells per ml by OD 600 . Y. pseudotuberculosis (5 3 10 7 ) and A. muciniphila (2 3 10 7 ) were mixed first with 60 ll of PBS with 20 mM ethylenediamine tetraacetic acid (EDTA) (complementinhibited) or PBS only (complement activation permitted), and thereafter with 60 ll of PIBD patient serum. In addition, to boost complement activation by the classical pathway, we added serum from a Y. pseudotuberculosis-infected patient that contains antibodies against Y. pseudotuberculosis together with Y. pseudotuberculosis bacteria to induce activation of complement system. Fifty ll of Y. pseudotuberculosis (5 3 10 7 ) in PBS was mixed with 10 ll of serum from the Y. pseudotuberculosis-infected patient and 60 ll of PIBD patient serum. To establish the background levels of complement activation products in the patient sera, samples were mixed (1 : 1) with 20 mM EDTA in PBS and stored at 2708C. To activate complement the patient sera were incubated for 20 min at 1378C with shaking at 500 rpm. The reaction was stopped by transferring the tubes into ice and adding EDTA to a final concentration of 10 mM. Bacterial cells were separated from sera by centrifugation at 5900 g for 3 min and the sera were stored at 2708C for subsequent C3a and soluble terminal complement complex (SC5b-9) analysis.
The level of complement activity was determined as formation of C3a, an anaphylatoxic marker of the early complement pathway activation, and as soluble terminal complement complex (TCC, SC5b-9), indicating activation of the terminal pathway. Complement C3a and SC5b-9 were analysed from the serum samples using the commercial MicroVue C3a kit (Quidel; Tecomedical, Sissach, Switzerland), which measures the amount of C3a-desArg, and SC5b-9 Plus enzyme immune assay kit (Quidel; Tecomedical), which measures the amount of TCC. For C3a measurements, serum samples from 23 patients (n 5 23) were diluted 1 : 10 000, and for SC5b-9 serum samples from 26 patients (n 5 26) were diluted 1 : 160 to final concentrations for the measurements. All analyses were carried out in duplicate.
Statistical analyses
The statistical calculations in the Complement Study were performed using SPSS Statistics (version 21.0; IBM, Armonk, New York, NY, USA). Data are presented as median [interquartile range (IQR)] or median (min-max) due to the small numbers in a group (C4A deficiency group). The Mann-Whitney U-test was used to assess the association between the concentration of C3a and TCC among the groups having different C4 gene numbers. Spearman's rank correlation test and Fisher's exact test were used for statistical comparison between serum complement values and clinical features and genetic differences.
In the Microbiota Study, the statistics were performed using the software environment R (the R Foundation) [36] , using the packages vegan [37] , mare [38] and beanplot [39] . The microarray signal intensities were transformed into relative abundances of bacterial taxa by dividing the summarized signal intensity for the taxon with the total signal intensities for the sample. The microbiota composition and similarity to control microbiota (average correlation between the patient microbiota profile and that in controls) in the patients were analysed previously [18] . Microbial diversity was calculated as the inverse Simpson diversity index. Linear models were used to analyse the association between the number of C4 genes and the microbiota diversity and similarity to control microbiota. Generalized linear models with negative binomial distribution were used for assessment of the association between genotype and bacterial genus-like group abundances. The association between calprotectin and genotype was assessed using a linear model with log-transformed calprotectin values, adjusting for anti-tumour necrosis factor (TNF)-a medication, microbial diversity and similarity to control microbiota. A difference with a P-value < 0Á05 in a twotailed test was considered significant.
Results
C4 gene numbers in the PIBD patients
The basic characteristics of the paediatric IBD patients are presented in Table 1 . The disease progress of patients was, in general, more severe in the Complement Study than in the Microbiota Study patients. As many as 61Á5% of patients in the Complement Study and 23Á1% (P 5 0Á001, Fisher's exact test) in the Microbiota Study needed anti-TNF-a medication, and 23Á1% in the Complement Study and 4Á3% (P 5 0.021) in the Microbiota Study underwent surgery for IBD. Three (11Á5%) patients had fistula in the Complement Study and one (2Á1%, P 5 0Á126) in the Microbiota Study. Five out of six of those who underwent surgery in the Complement Study had only one C4B gene. Also, both of those who underwent surgery in the Microbiota Study had one C4B gene. The distribution of C4A and C4B gene numbers in the patients of the study groups are presented in Table 2 .
C4B gene number is associated with microbiota composition and diversity Calprotectin levels in stools were measured from the study subjects in the Microbiota Study. The levels were associated significantly positively with the number of C4B genes (trend: P 5 0Á0002) and with the total number of C4 genes (P < 0Á0001), indicating that the C4 genotype and subsequently higher amounts of C4 were associated with intestinal inflammation (Fig. 1) . This effect was independent of anti-TNF-a medication and the microbiota composition and diversity, as the relationship remained significant after adjustment for these (trend: P 5 0Á0001 for C4B and P < 0Á0001 for total C4). The C4A gene number was not associated with calprotectin levels (P 5 0Á6).
Microbial diversity in the faecal samples (trend: P 5 0Á008), the similarity to control microbiota index (trend: P 5 0Á006) and the relative abundance of butyrateproducing bacteria (trend: P 5 0Á024) were correlated significantly negatively with C4B gene number in patients (Fig. 2) . In contrast, the C4A gene number was not associated with either microbial diversity (trend: P 5 0Á51), butyrate producers (trend: P 5 0Á042) or similarity to control microbiota (trend: P 5 0Á61). The total C4 gene number (C4A 1 C4B) was correlated negatively with both microbial diversity and similarity to control microbiota (trends: P 5 0Á03 and P 5 0Á01, respectively), but not significantly with butyrate producers (trend: P 5 0Á09). The correlations were not confounded by current inflammation or anti-TNF-a treatment: after controlling for calprotectin level and the use of anti-TNF-a medication, diversity and similarity to control, microbiota remained associated significantly with the C4B gene number (P 5 0Á007, P 5 0Á03, respectively) and borderline significant with the total C4 gene number (P 5 0Á06, and P 5 0Á06, respectively).
At the level of individual genus-level groups, the C4B gene number was correlated significantly [false discovery rate (FDR)-corrected P-value < 0Á05] negatively with several butyrate producers (relatives of Eubacterium, Lachnospira and Ruminococcus) and positively with the Gram-negative LPS-producing enterobacteria (relatives of Klebsiella, Escherichia and Serratia) (Supporting information, Fig. S1 ).
C4B gene number and complement C3a generation in patient sera
To determine whether the C4A and C4B gene numbers translate into the extent of bacteria-induced complement activation, serum samples from PIBD patients (n 5 23, the Complement Study) were stimulated with intestinal pathogenic Y. pseudotuberculosis bacteria and commensal mucindegrading A. muciniphila bacteria. No differences in serum C3a, an indicator of activation of early pathways of the complement system, were seen before or after any stimulation between the groups having zero, one or two copies of C4B ( Fig. 3a and Supporting information, Table S1 ) or CD 5 Crohn's disease; IBDU 5 unclassified inflammatory bowel disease; UC 5 ulcerative colitis. Fig. 1 . Faecal calprotectin levels (lg/g) and (a) total C4, (b) C4A and (c) C4B gene numbers in paediatric inflammatory bowel disease (PIBD) patients in the microbiota study. The P-value in the upper left corner of box-plot shows testing for linear trend in the three categories. The significant differences in the log-transformed calprotectin levels between total C4, C4A and C4B genotype groups were analysed using analysis of variance. The P-values represent comparisons between the lowest group and the group with P-values shown.
between the C4 deficiency group (< 4 C4A/B) and the normal C4 copy number group (! 4 copies of C4A/B) ( Fig. 3c and Supporting information, Table S2 ). Serum C3a was higher in the C4A-deficient group (< 2 C4A genes, n 5 3) when compared to the normal C4A group (n 5 20) only after serum stimulation with Y. pseudotuberculosis with serum from a Y. pseudotuberculosis-infected patient (P 5 0Á018, Supporting information, Table S3 ).
C4B gene number and TCC generation in patient sera
TCC levels were determined to measure terminal pathway complement activation. At baseline (without any stimulation), TCC levels varied between the groups (Fig. 3b and Supporting information, Table S1 ). Those with two C4B genes [median (IQR): 3999 (2155) ng/ml] had higher TCC levels than those with one C4B gene (3049 (1152) ng/ml; P 5 0Á05). The bacterial activation increased serum TCC levels from 3Á3 (between stimulation with PBS and A. muciniphila) to 13Á3-fold (between PBS and Y. pseudotuberculosis with serum of a Y. pseudotuberculosis-infected patient), when all the patients were analysed together (Supporting information, Table S1 ). Serum TCC generation was significantly weaker among patients with no C4B genes compared to groups having one or two copies of C4B (Fig. 3b, Supporting information ,  Table S2 ). When stimulated with Y. pseudotuberculosis and Fig. 2 . Associations of C4A, C4B and total C4 gene numbers with (a-c) microbial diversity, (d-f) similarity to control microbiota and (g-i) butyrate producers in the faecal samples of the paediatric inflammatory bowel disease (PIBD) patients of the microbiota study. The violin plots show the shape of distribution and the average value (long bar) for the groups and values for individual patients (small bar). Upper panels show microbiota diversity in patient groups with different C4 gene numbers. Significant differences in diversity (b) between the groups with no and one C4B gene (P 5 0Á044) and between the groups with no and two C4B genes (P 5 0Á041) were detected as determined by the Mann-Whitney U-test (two-tailed). The middle panels represent deviation of microbiota of patients with different C4 genotype groups from microbiota of controls with unknown C4 genotypes (1 5 identical to microbiota of healthy subjects (n 5 26) [18] ). The lower panels show the abundance of butyrate producers in the C4 genotype patient group. immune patient serum the group with no C4B genes had lower serum TCC levels [17107 (19899) ng/ml] than the group with one C4B gene [37365 (35153) ng/ml, P 5 0Á05] and the group with two C4B genes [42636 (23881) ng/ml, P 5 0Á005; Supporting information, Table S1 ]. Similarly, when stimulated with A. muciniphila the group with no C4B genes generated significantly less serum TCC [9505 (4638) ng/ml] than the group with one C4B gene [18666 (11664) ng/ml, P 5 0Á039] or two C4B genes [17194 (5129) ng/ml, P 50Á025] (Fig. 3b, Supporting information, Table S1 ). No significant difference was seen when serum samples were stimulated with Y. pseudotuberculosis alone (P 5 0Á118).
When the effect of the total C4 gene numbers was assessed, serum TCC generation was found to be significantly lower in the C4-deficient group [17107 (19899) ng/ ml] than in the normal C4 gene number group [28372 (38293) ng/ml; P 5 0Á014] after stimulation with Y. pseudotuberculosis (Fig. 2d, Supporting information, Table S2 ). No significant differences were seen between C4A gene number groups (Supporting information, Table S2 ).
Discussion
In order to elucidate the influence of complement C4 gene number on host-microbe interaction in an inflammatory disease, we collected samples from paediatric IBD patients to assess the in-vivo and in-vitro associations between C4 gene number and host-microbe interactions. We found that C4B, but not C4A, could be involved in the aberrant host reactivity to gut microbiota in children with IBD. C3a and TCC levels in PIBD patient sera are presented as mean 6 standard error of the mean. The MannWhitney U-test (two-tailed) was used for statistical analysis of differences between the groups. Comparisons were performed between the group having no and one or two copies of the C4B gene and between the C4-deficient group (having fewer than four gene copies of C4A/B) and the nondeficient group (four or more gene copies of C4A and C4B).
Our study shows that both the total number of complement C4 genes (C4A/B) and particularly the C4B gene number have an impact upon serum complement response, with influence on the gut inflammation and microbiota composition in vivo. The more C4B genes are expressed, the stronger is the complement activation response at the terminal pathway (TCC) and the more aberrant is the microbiota composition in PIBD patients. This finding indicates that while C4 is needed for complementmediated clearance of microbes and cell debris, the activity of C4, and particularly of C4B, can be related to complement over-reactivity under pathological inflammatory conditions, such as IBD, leading to tissue injury. The potential mechanisms for the link between complement C4 and inflammatory bowel disease include microbe-mediated complement activation, complement-activation response to injury and disturbed regulation of complement activation. C4B is known to have a role in binding to hydroxyl groups of foreign carbohydrate antigens and in the activation of the classical and lectin C pathways, leading to the Fig. 4 . A schematic presentation of the influence of C4B gene number on host immune functions and microbiota in paediatric inflammatory bowel disease. (a) The complement system can be initiated in three distinct ways: the classical, the lectin or the alternative pathway. (b) These pathways merge to activate C3 to C3a and C3b and continue as a common terminal pathway. (c) If the complement system is activated fully it leads to the removal of bacteria through bacteriolysis by the membrane attack complex or phagocytosis of C3b/iC3b-opsonized bacteria by neutrophils or macrophages. The genetically normal situation with the presence of one to two C4B genes in children with inflammatory bowel disease (IBD) in this study is linked to a stronger complement activation, intestinal inflammation and lower diversity in microbiota. Patients without C4B genes have less complement activation, intestinal inflammation and healthier type microbiota. Thereby, they seem to be protected from the inflammatory state and disturbed microbiota. C4 is shown in red. Complement activation was measured from bacteria-stimulated IBD patient serum by analysing C3a and soluble terminal complement complex (SC5b-9) levels (shown in green). C3a 5 C3 activation product, an anaphylatoxin; C4 5 complement component 4; TCC 5 terminal complement complex including complement proteins C5b-C9. TCC indicates both the soluble form (SC5b-9) and the complement membrane attack complex (MAC). formation of the membrane attack complex [40] . Thus, an excessive response, especially to microbial lipopolysaccharides carrying hydroxyl groups, could lead to inflammation. Similarly, injured tissue structures could activate complement and lead to increased contacts of microbes with the complement system. The responses would be excessive, particularly if the ability to control complement activation at the local sites is compromised. The reason for increased complement activation response is due probably to a quantity effect: more C4B leads to more activation. This may, however, not be the whole truth. Another possibility could be that, in the absence of C4B genes, the activation is diverted towards a less inflammatory pathway against bacteria via the C4A-protein. This is suggested by the fact that the number of C4A genes was not related to the examined inflammation parameters.
C4B deficiencies are common, but the reasons for their potential evolutionary survival advantage are unknown. It is possible that a limited deficiency of C4B helps to curb chronic inflammation, for example, in IBD patients. Conversely, deficiencies of C4, particularly of C4A, may be deleterious in other cases, such as in systemic lupus erythematosus patients [41] . C4 deficiencies may even promote the onset of IBD [15] by compromising the host's ability to control the microbiota. The observed association between genotype, host response and microbiota composition is in line with the paradigm of microbiota-dependent genetically determined inflammation in IBD [17] . Phenotypical C4 deficiencies can be the result of increased protein consumption or genetic deficiencies caused by deletions, conversions or silencing mutations [21] . C4 deficiency can lead to insufficient complement activation and impaired removal of not only microbes, but also of other unwanted material, including apoptotic cells and extracellular debris from the body. The inefficiency of complement-mediated clearance in C4B-deficient patients could contribute to the poor recovery after surgery of these patients [15] .
In this study, TCC was a better marker for in-vitro complement activation, reflecting the presence of the C4B gene, than C3a, which is being formed constantly even in the absence of bacterial stimulation [42] via the alternative C pathway. Limited correlation between C3a and TCC levels may thus be due possibly to spontaneous C3a formation via alternative pathway amplification in the serum [42] . The benefit of TCC is that it also indicates C5 activation, which is otherwise difficult to measure directly in patient samples. C5a is a more potent mediator of inflammation than C3a. C4 gene products are involved in the classical and lectin pathways, but not in the alternative pathway activation [6] . This could explain why we did not see differences in C3a levels between groups of patients with different C4 gene numbers. [6] The alternative pathway is important in protection against microbes, but it also acts as an amplifying cascade for the classical and lectin pathways. In this study we did not distinguish whether complement became activated via the classical or the lectin pathway. Antibodies are needed for the specific recognition of microbes and activation of the classical pathway. Also, both the classical and the lectin pathways contribute significantly to the direct recognition of microbes via their sensor molecules C1q and the ficolins, and to a certain extent by mannose-binding lectin (MBL) (especially for yeast). The ficolins are particularly intriguing, because they recognize a wide profile of distinct carbohydrate structures. Figure 4 summarizes the model explaining the findings of the present study, and illustrates the role of C4B on complement activation in PIBD patients. No changes at the early pathway of complement, measured as C3a formation, were seen between the C4B or total C4 genotype groups. A high C3a level could have been generated via the alternative pathway that does not include C4. Low C4B and low total C4 gene numbers and high diversity in microbiota associated with lower levels of terminal pathway complement activation after bacterial stimulation. This may indicate two issues. First, complement C4 is needed for efficient complement activation up to the terminal stages. Secondly, if complement activation is insufficient a more diverse microbial community in the intestines may flourish. In other words, complement emerges as one inflammatory factor that may modulate the microbial diversity in the gut.
The novel findings of the present study include a link between the C4B gene number, inflammation and reduced intestinal microbial diversity in IBD. In a larger context, this information could be utilized to provide better and individually tailored treatment for paediatric patients. The data confirm the genetic heterogeneity of the patients and suggest that the presence of complement components could have a role in determining the inflammatory status and diversity of microbiota in the IBD patients. Also, genetically determined complement activation status may play a role in therapeutic responses. The level of plasma complement activation via the classical pathway was reduced after treatment of Crohn's disease patients with infliximab [43] . A potential link between C4 and TNF genes exists, because they are both located in the MHC class III region [44] . In future, analyses of the role of complement in IBD subtypes and studies with larger study populations could provide further important information for the development of complement-modulating therapy for these patients.
The complement protein C3 is structurally similar to C4 but, by being outside the MHC region, it has less polymorphism and no gene copy number variation. Interestingly, however, Elmgreen et al. have observed that the functionally abnormal C3F gene variant, showing increased responses, e.g. against yeast, occurs at an increased frequency in Crohn's disease [45] .
Overall, the results suggest that C4B, but not C4A, is involved in the aberrant inflammatory response of the host towards the microbiota in PIBD. C4A is thought to be more important in immune clearance [46] , while C4B is used more specifically in defence against microbes [40] . The biochemical background for this is the stronger reactivity of C4A towards amino groups in proteins and of C4B towards hydroxyl groups prevalent, for example, in carbohydrates such as microbial capsules and lipopolysaccharides [47] . Reduced complement attack against bacteria, as seen in C4B-deficient patients, appears to dampen the inflammatory response of the host towards the microbiota and to allow a wider diversity of microbiota composition. The observation of a 'normal-appearing' microbiota in C4B-deficient IBD patients suggests that the disease aetiology is related to aberrant host responses to normal microbiota driving the microbiota into a dysbiotic, inflammation-tolerant state, rather than the other way around. We have shown previously that the clinical outcome of anti-TNF-a therapy is dependent upon the microbiota composition: patients with normal-appearing microbiota are likely to respond to the treatment [15] . Together, these results suggest that the C4B genotype, which is associated with microbiota composition, may associate with anti-TNF-a responses.
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Additional Supporting information may be found in the online version of this article at the publisher's web-site: Fig. S1 . Correlations between paediatric inflammatory bowel disease (PIBD) patient C4B gene number and the level of individual genus-level groups. Table S1 . Paediatric inflammatory bowel disease (PIBD) patient serum complement activation determined by early pathway (C3a) and terminal pathway (TCC) distributed based on total C4 (C4A1C4B) gene number. Sera of patients were subjected to no stimulation (baseline), stimulation treatment by no bacteria [phosphate-buffered saline (PBS), treatment baseline], Yersinia pseudotuberculosis, Y. pseudotuberculosis with serum including antibodies against Y. pseudotuberculosis and Akkermansia muciniphila. Table S2 . Paediatric inflammatory bowel disease (PIBD) patient serum complement activation determined by early pathway (C3a) and terminal pathway (TCC) distributed based on total C4 (C4A1C4B) gene number. Sera of patients was subjected to no stimulation (baseline), stimulation treatment by no bacteria [phosphate-buffered saline (PBS), treatment baseline], Yersinia pseudotuberculosis, Y.
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